Thus, the combination of impaired secretion of glucagon and non-physiological distribution of injectable insulin contributes to a higher risk of hypoglycaemic events and long-term micro- and macrovascular complications in diabetes patients [16, 17]. Here, INS is linked to diabetes mellitus.